MiCAN Technologies

MiCAN Technologies is a Kyoto University spinout company founded in 2016, with a focus on providing high precision artificial blood cells using iPSC technologies. The company's slogan, "Providing high precision artificial blood cells using iPSC technologies," reflects its core mission. MiCAN has developed production technologies to generate high-performance artificial blood cells from stem cells. Their Mylc cell series, particularly the cMylc kit, has garnered attention for its suitability in evaluating the efficacy of drug discovery and safety assessment, specifically in the context of COVID-19 vaccines and drug development. The company's coronavirus-optimized myeloid lineage cells are designed to serve as host cells, offering stable and robust performance for research on COVID-19. MiCAN Technologies secured a ¥128.00M Corporate Round investment on 23 August 2019, with investments from notable entities such as Osaka University Venture Capital, Graduate School of Management, and GLOBIS University. The startup operates in the Health Care industry and is headquartered in Japan.